Niruma Life Sciences Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 06-07-2024
- Paid Up Capital ₹ 0.10 M
as on 06-07-2024
- Company Age 4 Year, 5 Months
- Last Filing with ROC 31 Mar 2023
- Revenue %
(FY 2023)
- Profit -14.24%
(FY 2023)
- Ebitda -48.40%
(FY 2023)
- Net Worth -10.61%
(FY 2023)
- Total Assets 0.17%
(FY 2023)
About Niruma Life Sciences
The Corporate was formerly known as Dkm Medical Systems Private Limited. The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Vinod Gupta, Mitesh Gupta, and Sakshi Gupta serve as directors at the Company.
- CIN/LLPIN
U85100RJ2020PTC069304
- Company No.
069304
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
29 Jun 2020
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Jaipur
Industry
Company Details
- Location
Jaipur, Rajasthan, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Niruma Life Sciences?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Vinod Gupta  | Director | 29-Jun-2020 | Current |
| Mitesh Gupta | Director | 29-Jun-2020 | Current |
| Sakshi Gupta | Director | 29-Jun-2020 | Current |
Financial Performance and Corporate Structure Insights of Niruma Life Sciences.
Niruma Life Sciences Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a substantial fall in profitability, with a 14.24% decrease in profit. The company's net worth observed a substantial decline by a decrease of 10.61%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Niruma Life Sciences?
Unlock access to Niruma Life Sciences's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
- Jaipur Nuclear & Imaging Center Private LimitedActive 20 years 6 months
Mitesh Gupta and Sakshi Gupta are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Niruma Life Sciences?
Niruma Life Sciences has a workforce of 0 employees as of Mar 29, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Niruma Life Sciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Niruma Life Sciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
